ImageneBio (IMA) FY2025 10-K Risk Factors: 71 New, 76 Dropped

What the changes say

ImageneBio completed a merger in July 2025, divested non-IMG-007 assets, and is now entirely dependent on IMG-007 for atopic dermatitis and other immunological indications.

What changed since the prior 10-K

New

NewRisks Related to Our Limited Operating History, Financial Position and Need for Additional Capital
We are a clinical-stage biopharmaceutical company with a limited operating history, which may make it difficult to evaluate our current business and predict our future performance
As a clinical-stage biopharmaceutical company with a limited operating history, we have no approved products and have never generated product revenue.
NewRisks Related to Our Limited Operating History, Financial Position and Need for Additional Capital
We expect to incur significant losses for the foreseeable future and may never achieve or maintain profitability
We incurred net losses of $45.3 million for 2025 and $36.6 million for 2024, with an accumulated deficit of $230.1 million as of December 31, 2025.
NewRisks Related to Our Limited Operating History, Financial Position and Need for Additional Capital
our implementation of additional internal systems and infrastructure, including operational, financial and management information systems
Raising additional capital through equity or debt may cause dilution or impose restrictive covenants limiting our business activities.
NewRisks Related to the Discovery and Development of our Product Candidates
Our business is entirely dependent on the success of IMG-007 for the treatment of AD and for other potential indications
Following the divestiture of our non-OX40 business, our entire business depends on the success of IMG-007 in atopic dermatitis and other indications.
NewRisks Related to the Discovery and Development of our Product Candidates
Clinical trials are expensive, time-consuming, difficult to design and implement, and have an uncertain outcome. Further, we may encounter substantial delays in our clinical trials
Clinical trials are lengthy, expensive, and subject to uncertain outcomes and rigorous regulatory reviews for safety, purity, and potency.
NewRisks Related to the Discovery and Development of our Product Candidates
failure to manufacture sufficient quantities of IMG-007 or any future product candidates for use in clinical trials
We may fail to manufacture sufficient quantities of IMG-007 or encounter unforeseen clinical trial delays due to regulatory changes or slow patient enrollment.
NewRisks Related to the Discovery and Development of our Product Candidates
any future collaborators that conduct clinical trials may face any of the above issues, and may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for us
Unfavorable clinical trial results or safety concerns could lead to unplanned costs, delayed approvals, or approval restrictions including boxed warnings.
NewRisks Related to the Discovery and Development of our Product Candidates
have the product removed from the market after obtaining marketing approval
Regulatory authorities or data safety boards may suspend or terminate clinical trials due to safety issues, protocol noncompliance, or lack of funding.
NewRisks Related to the Discovery and Development of our Product Candidates
Enrollment and retention of patients in clinical trials is an expensive and time-consuming process subject to various external factors beyond our control that may cause delays or complications
Slow patient enrollment and retention in clinical trials due to competing therapies can delay our trial completion and regulatory submissions.
NewRisks Related to the Discovery and Development of our Product Candidates
the risk that patients enrolled in clinical trials will not remain in the trial through the completion of evaluation
Competition from other clinical trials targeting immunological and inflammatory diseases reduces our available patient pool and qualified investigators.
NewRisks Related to the Discovery and Development of our Product Candidates
We may not identify or discover other product candidates and may fail to capitalize on product candidates that may present a greater commercial opportunity or for which there is a greater likelihood of success
Identifying new product candidates requires substantial resources, and target changes may necessitate new contract manufacturing organizations, slowing development.
NewRisks Related to the Discovery and Development of our Product Candidates
a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors
Inaccurate market estimates or poor commercialization choices could cause us to relinquish valuable rights or misallocate internal resources.
NewRisks Related to the Discovery and Development of our Product Candidates
Our future preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all
NewRisks Related to the Discovery and Development of our Product Candidates
The affected populations for IMG-007 or any future product candidates may be smaller than we or third parties currently project, which may affect the addressable markets for IMG-007 or any future product candidates
NewRisks Related to the Discovery and Development of our Product Candidates
ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations
NewRisks Related to the Discovery and Development of our Product Candidates
International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects
NewRisks Related to Manufacturing and Our Reliance on Third Parties
Our ability to generate revenue and achieve profitability from third party licensed product candidates also depends upon our ability to obtain and retain exclusivity on the licensed product candidates and related product candidates controlled by the licensor
NewRisks Related to Manufacturing and Our Reliance on Third Parties
the priority of invention of patented technology
NewRisks Related to Manufacturing and Our Reliance on Third Parties
Pursuant to the terms of the license agreements with certain of our licensors, the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity or unenforceability of these patents
NewRisks Related to Manufacturing and Our Reliance on Third Parties
Our rights to develop and commercialize IMG-007 are subject, in part, to the terms and conditions of licenses granted to us by others
NewRisks Related to Manufacturing and Our Reliance on Third Parties
carrier disruptions or increased costs that are beyond our control
NewRisks Related to Manufacturing and Our Reliance on Third Parties
Some of our suppliers may experience disruption to their respective supply chain due to the effects of macroeconomic conditions, which could delay, prevent or impair our development or commercialization efforts
NewRisks Related to Manufacturing and Our Reliance on Third Parties
collaborators may own or co-own intellectual property covering IMG-007 or any future product candidates that results from our collaborating with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property
NewRisks Related to Commercialization of Our Product Candidates
We face substantial competition from other pharmaceutical and biotechnology companies, and our operating results may suffer if we fail to compete effectively
NewRisks Related to Commercialization of Our Product Candidates
Coverage and reimbursement may be limited or unavailable in certain market segments for IMG-007 or any future product candidates, which could make it difficult for us to sell for IMG-007 or any future product candidates, if approved, profitably
NewRisks Related to Commercialization of Our Product Candidates
Clinical trial subject injury and product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of IMG-007 or any future product candidates that we may develop
NewRisks Related to Government Regulation
The BLA and similar applications must also include significant information regarding the chemistry, manufacturing and controls for the product, including with respect to chain of identity and chain of custody of the product
NewRisks Related to Government Regulation
changes in the approval policies or regulations that render our preclinical and clinical data insufficient for approval
NewRisks Related to Government Regulation
We have conducted and intend to conduct certain of our clinical trials globally. However, the FDA and other foreign equivalents may not accept data from such trials, in which case our development plans may be delayed, which could materially harm our business
NewRisks Related to Government Regulation
We may seek special designations by the regulatory authorities to expedite regulatory approvals, but may not be successful in receiving these designations, and even if received, they may not benefit the development and regulatory approval process
NewRisks Related to Government Regulation
marketing approvals, our target market will be reduced and our ability to realize the full market potential of IMG-007 and any future product candidates will be harmed
NewRisks Related to Government Regulation
We and any of our third-party manufacturers or suppliers may use potent chemical agents and hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly
NewRisks Related to Government Regulation
federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers
NewRisks Related to Government Regulation
IMG-007 will be regulated as a biologic, and therefore they may be subject to competition sooner than anticipated
NewRisks Related to Government Regulation
Even if we obtain regulatory approval of IMG-007 or any future product candidates, the products may not gain market acceptance among physicians, patients, hospitals and others in the medical community
NewRisks Related to Government Regulation
the effectiveness of our sales and marketing efforts
NewRisks Related to Government Regulation
The advancement of healthcare reform may negatively impact our ability to profitably sell IMG-007 or any future product candidates, if approved
NewRisks Related to Government Regulation
Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability
NewRisks Related to Government Regulation
standards, external and internal privacy and security policies, contractual requirements and other obligations relating to data privacy and security, including in connection with clinical trials in the United States and abroad
NewRisks Related to Government Regulation
the violator. India’s new privacy legislation, the Digital Personal Data Protection Act (“DPDP”), may also apply to our operations
NewRisks Related to Government Regulation
Our activities may subject us to various laws relating to foreign and U.S. investments and other transactions, and our failure to comply with these laws could subject us to substantial fines and other penalties, which could adversely affect our business
NewRisks Related to Government Regulation
The CFIUS Regulations authorize CFIUS to review certain foreign investments in and acquisitions of U.S. businesses, and to prohibit, modify, or unwind transactions subject to CFIUS jurisdiction in the event the transaction is determined to raise national security concerns
NewRisks Related to Our Intellectual Property
If we are unable to obtain and maintain patent protection for IMG-007 or any future product candidates or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets
NewRisks Related to Our Intellectual Property
Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
NewRisks Related to Our Intellectual Property
We enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world
NewRisks Related to Our Intellectual Property
If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of marketing exclusivity for IMG-007 or any future product candidates, our business may be harmed
NewRisks Related to Our Intellectual Property
Our proprietary rights may not adequately protect IMG-007 or any future product candidates, and do not necessarily address all potential threats to our competitive advantage
NewRisks Related to Our Intellectual Property
the patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on our business
NewRisks Related to Our Intellectual Property
If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
NewRisks Related to Our Intellectual Property
We may need to license additional intellectual property from third parties, and any such licenses may not be available or may not be available on commercially reasonable terms
NewRisks Related to Our Intellectual Property
We may fail to obtain or enforce assignments of intellectual property rights from our employees and contractors
NewRisks Related to Our Intellectual Property
Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information
NewRisks Related to Our Intellectual Property
We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties
NewRisks Related to our Industry and Business
We will need to expand our organization, and we may experience challenges in managing this growth as we build our capabilities, which could disrupt our operations
NewRisks Related to our Industry and Business
Our business is subject to risks arising from pandemic and epidemic diseases
NewRisks Related to our Industry and Business
We or the third parties upon whom we depend may be adversely affected by a fire and earthquake or other man-made or natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster
NewRisks Related to our Industry and Business
Our insurance policies may be inadequate, may not cover all of our potential liabilities and may potentially expose us to unrecoverable risks
NewRisks Related to our Industry and Business
Our business could be affected by litigation, government investigations, and enforcement actions
NewRisks Related to our Industry and Business
Our employees and independent contractors, including consultants, vendors and any third parties we may engage in connection with development and commercialization may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could harm our business
NewRisks Related to our Industry and Business
Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations
NewRisks Related to Ownership of Our Common Stock
The market price of our common stock is expected to be volatile
NewRisks Related to Ownership of Our Common Stock
Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common stock
NewRisks Related to Ownership of Our Common Stock
We will incur significant legal, accounting and other expenses that Legacy Inmagene did not incur as a private company, including costs associated with public company reporting requirements
NewRisks Related to Ownership of Our Common Stock
An active trading market for our common stock may not develop and our stockholders may not be able to resell their shares of common stock for a profit, if at all
NewRisks Related to Ownership of Our Common Stock
Substantial future sales of shares of our common stock could adversely affect the market price of such shares
NewRisks Related to Ownership of Our Common Stock
If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline
NewRisks Related to Ownership of Our Common Stock
However, this material weakness could result in a misstatement of substantially all of our accounts or disclosures that would result in a material misstatement of our annual or interim financial statements that would not be prevented or detected
NewRisks Related to Ownership of Our Common Stock
Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired
NewRisks Related to Ownership of Our Common Stock
The increasing use of social media platforms presents new risks and challenges
NewRisks Related to Ownership of Our Common Stock
Unstable market and economic conditions, including any adverse macroeconomic conditions or geopolitical events, may have serious adverse consequences on our business, financial condition and stock price
NewRisks Related to Ownership of Our Common Stock
We could be subject to securities class action litigation

Dropped

DroppedRisks Related to Our Strategic Alternatives Review Process
We undertook a comprehensive review of strategic alternatives, including identifying and reviewing potential candidates for a merger
We undertook a comprehensive review of strategic alternatives, including identifying and reviewing potential candidates for a merger.
DroppedRisks Related to Our Strategic Alternatives Review Process
we could potentially lose key personnel during the pendency of the Merger; and
We could potentially lose key personnel during the pendency of the Merger.
DroppedRisks Related to Our Strategic Alternatives Review Process
The occurrence of any of these events individually or in combination could materially and adversely affect our results of operations, business, and our common stock price
If we do not successfully consummate the Merger, our board may pursue dissolution and liquidation.
DroppedRisks Related to Our Strategic Alternatives Review Process
We are substantially dependent on our remaining employees to facilitate the consummation of the Merger
We had only 10 full-time employees as of February 28, 2025.
DroppedRisks Related to Our Strategic Alternatives Review Process
Even if we are successful in completing a strategic transaction, we may be exposed to other operational and financial risks
Negotiation and consummation of a strategic transaction diverts management's attention and may disrupt our business.
DroppedRisks Related to Our Strategic Alternatives Review Process
If we do not complete the Merger, we may face substantial competition for attractive counterparties for any proposed strategic transactions
If the Merger is not completed, we may face substantial competition for attractive counterparties.
DroppedRisks Related to Our Strategic Alternatives Review Process
We have never paid and, other than in connection with the Merger, do not intend to pay any cash dividends in the foreseeable future, so any returns will be limited to the value of our capital stock
We have never paid and do not intend to pay any cash dividends in the foreseeable future.
DroppedRisks Related to Our Strategic Alternatives Review Process
We may become involved in litigation, including securities class action litigation, which could divert management’s attention and harm our business, and insurance coverage may not be sufficient to cover all costs and damages
We may become involved in litigation, including securities class action litigation following significant transactions.
DroppedRisks Related to Our Limited Operating History, Financial Position, and Capital Requirements
We are a targeted oncology company with a limited operating history
We are a targeted oncology company with a limited operating history commencing in 2016.
DroppedRisks Related to Our Limited Operating History, Financial Position, and Capital Requirements
We have incurred significant net losses since our inception and, if we continue to progress the development of our product candidates, anticipate that we will continue to incur losses for the foreseeable future
Our net losses were $49.2 million and $68.2 million for the years ended December 31, 2024 and 2023.
DroppedRisks Related to Our Limited Operating History, Financial Position, and Capital Requirements
future accounting pronouncements or changes in our accounting policies
Future accounting pronouncements or changes in accounting policies could result in operating result fluctuations.
DroppedRisks Related to Our Limited Operating History, Financial Position, and Capital Requirements
We have no products approved for commercial sale and have not generated any revenue from product sales
We have generated minimal collaborative revenue and no product sales to date.
DroppedRisks Related to Our Limited Operating History, Financial Position, and Capital Requirements
maintain a continued acceptable safety profile of our products following approval
DroppedRisks Related to Our Limited Operating History, Financial Position, and Capital Requirements
the costs of establishing or contracting for sales and marketing capabilities if we obtain regulatory approvals to market our product candidates
DroppedRisks Related to Our Limited Operating History, Financial Position, and Capital Requirements
Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates
DroppedRisks Related to Our Limited Operating History, Financial Position, and Capital Requirements
We have recently undertaken internal restructuring activities, and may do so again in the future. The assumptions underlying these activities may prove to be inaccurate, or we may fail to achieve the expected benefits therefrom
DroppedRisks Related to the Development of our Targeted Oncology and Other Programs and Product Candidates
If we continue to progress the development of our product candidates, we may not be able to successfully complete clinical trials for our ongoing targeted oncology program or our current product candidate
DroppedRisks Related to the Development of our Targeted Oncology and Other Programs and Product Candidates
Our lead program is focused on the development of oncology therapeutics for patients with genetically defined or biomarker-driven cancers, which is a rapidly evolving area of science, and the approach we have taken to discover and develop drugs is novel and may never lead to approved or marketable products
DroppedRisks Related to the Development of our Targeted Oncology and Other Programs and Product Candidates
Clinical product development involves a lengthy and expensive process, with an uncertain outcome
DroppedRisks Related to the Development of our Targeted Oncology and Other Programs and Product Candidates
Interim, top-line, and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to confirmation, audit and verification procedures that could result in material changes in the final data
DroppedRisks Related to the Development of our Targeted Oncology and Other Programs and Product Candidates
If we continue to progress the development of our product candidates, we may incur additional costs or experience delays in initiating or completing, or ultimately be unable to complete, development and commercialization
DroppedRisks Related to the Development of our Targeted Oncology and Other Programs and Product Candidates
regulators may revise the requirements for approving our product candidates, or such requirements may not be as we currently anticipate
DroppedRisks Related to the Development of our Targeted Oncology and Other Programs and Product Candidates
If we continue to progress the development of our product candidates and experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented
DroppedRisks Related to the Development of our Targeted Oncology and Other Programs and Product Candidates
In addition, some of our competitors have ongoing clinical trials for product candidates that treat the same indications as do our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors’ product candidates
DroppedRisks Related to the Development of our Targeted Oncology and Other Programs and Product Candidates
factors we may not be able to control that may limit patients, principal investigators or staff or clinical site availability
DroppedRisks Related to the Development of our Targeted Oncology and Other Programs and Product Candidates
If we continue to progress the development of our product candidates, we may not be able to file INDs, or similar applications for our programs to commence clinical trials on the timelines we expect, and even if we are able to, the FDA or other regulatory authorities may not permit us to proceed
DroppedRisks Related to the Development of our Targeted Oncology and Other Programs and Product Candidates
Our clinical trials or those of our current or future collaborators may reveal significant adverse events not seen in our preclinical or nonclinical studies and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates
DroppedRisks Related to the Development of our Targeted Oncology and Other Programs and Product Candidates
We currently conduct clinical trials for our product candidates outside the United States, and the FDA, the EMA, the MHRA and comparable foreign regulatory authorities may not accept data from such trials
DroppedRisks Related to the Development of our Targeted Oncology and Other Programs and Product Candidates
If we continue to progress the development of our product candidates, we may fail to identify viable new product candidates for clinical development for a number of reasons. If we fail to identify additional product candidates, our business could be materially harmed
DroppedRisks Related to the Development of our Targeted Oncology and Other Programs and Product Candidates
it may take greater human and financial resources than we will possess to identify additional therapeutic opportunities for our product candidates, thereby limiting our ability to develop, diversify and expand our product portfolio
DroppedRisks Related to the Development of our Targeted Oncology and Other Programs and Product Candidates
the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change such that our clinical data are insufficient for approval
DroppedRisks Related to the Development of our Targeted Oncology and Other Programs and Product Candidates
Pandemics, epidemics, or any outbreak of an infectious disease, may materially and adversely affect our business and our financial results and could cause a disruption to the continued development of our product candidates
DroppedRisks Related to the Development of our Targeted Oncology and Other Programs and Product Candidates
If we continue to progress the development of our product candidates, we may need to reformulate our product candidates which could require additional nonclinical studies or clinical trials and delay the development or regulatory approval of such product candidates
DroppedRisks Related to Commercialization
We face substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully than we do if we continue to progress development
DroppedRisks Related to Commercialization
organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization
DroppedRisks Related to Commercialization
If the market opportunities for our programs and product candidates are smaller than we estimate or if any regulatory approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability will be adversely affected, possibly materially
DroppedRisks Related to Commercialization
If we continue to progress the development of our product candidates and our product candidates do not achieve broad market acceptance, the revenue that we generate from their sales may be limited, and we may never become profitable
DroppedRisks Related to Commercialization
events in targeted oncology, immune-oncology or the biopharmaceutical industry could also result in greater governmental regulation, stricter labeling requirements, and potential regulatory delays in the testing or approvals of our product candidates
DroppedRisks Related to Commercialization
potential product liability claims
DroppedRisks Related to Our Reliance on Third Parties
We do not have the ability to independently conduct clinical trials. We rely and expect to continue to rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct or otherwise support clinical trials for our product candidates
DroppedRisks Related to Our Reliance on Third Parties
form relationships with other entities, some of which may be our competitors
DroppedRisks Related to Our Reliance on Third Parties
We have entered into collaborations and may enter into additional collaborations in the future, and we might not realize the anticipated benefits of such collaborations
DroppedRisks Related to Our Reliance on Third Parties
In addition, funding provided by a collaborator might not be sufficient to advance product candidates under the collaboration
DroppedRisks Related to Our Reliance on Third Parties
Any one or more of these risks, if realized, could reduce or eliminate revenue from product candidates under our collaborations, and could have a material adverse effect on our business, financial condition, results of operations, and/or growth prospects
DroppedRisks Related to Our Reliance on Third Parties
Our product candidates may compete with other product candidates and approved products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us
DroppedRisks Related to Our Reliance on Third Parties
The third parties upon whom we rely for the supply of the active pharmaceutical ingredients used in our product candidates are our sole source of supply, and if we continue to progress the development of our product candidates, the loss of any of these suppliers could significantly harm our business
DroppedRisks Related to Our Reliance on Third Parties
We may seek to establish additional collaborations, and, if we are not able to establish them on commercially reasonable terms, or at all, we may have to alter our development and commercialization plans
DroppedRisks Related to Our Intellectual Property
If we are unable to adequately protect and enforce our trade secrets, our business and competitive position would be harmed
DroppedRisks Related to Our Intellectual Property
We may initiate, become a defendant in, or otherwise become party to lawsuits to protect or enforce our intellectual property rights, which could be expensive, time-consuming, and unsuccessful
DroppedRisks Related to Our Intellectual Property
Intellectual property litigation and administrative patent office patent validity challenges in one or more countries could cause us to spend substantial resources and distract our personnel from their normal responsibilities
DroppedRisks Related to Our Intellectual Property
We may not obtain or grant licenses or sublicenses to intellectual property rights in all markets on equally or sufficiently favorable terms with third parties
DroppedRisks Related to Our Intellectual Property
If we fail to comply with our obligations in any agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business
DroppedRisks Related to Our Intellectual Property
the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our future licensors and us and our partners
DroppedRisks Related to Our Intellectual Property
Intellectual property rights do not guarantee commercial success of current or future product candidates or other business activities. Numerous factors may limit any potential competitive advantage provided by our intellectual property rights
DroppedRisks Related to Government Regulation
We may seek priority review designation for one or more of our other product candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster regulatory review or approval process
DroppedRisks Related to Government Regulation
We may seek orphan drug designation for certain of our product candidates, and we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity
DroppedRisks Related to Government Regulation
A breakthrough therapy designation and fast track designation by the FDA, even if granted, may not lead to a faster development, regulatory review or approval process, and each designation does not increase the likelihood that any of our product candidates will receive regulatory approval in the United States
DroppedRisks Related to Government Regulation
Accelerated approval by the FDA, even if granted for our current or any other future product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive regulatory approval
DroppedRisks Related to Government Regulation
The FDA, the EMA, the MHRA and other regulatory authorities may implement additional regulations or restrictions on the development and commercialization of our product candidates, and such changes can be difficult to predict
DroppedRisks Related to Government Regulation
Healthcare legislative reform measures may have a material adverse effect on our business and results of operations
DroppedRisks Related to Government Regulation
If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
DroppedRisks Related to Government Regulation
European data collection is governed by restrictive regulations governing the use, processing and cross-border transfer of personal information
DroppedRisks Related to Government Regulation
Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain products outside of the United States and require us to develop and implement costly compliance programs
DroppedRisks Relating to Employee Matters and Managing Growth
We and our third-party providers may be unable to adequately protect our information systems from cyberattacks, which could result in the disclosure of confidential or proprietary information, including personal data, damage our reputation, and subject us to significant financial and legal exposure
DroppedRisks Relating to Employee Matters and Managing Growth
Artificial intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information, and personal data
DroppedRisks Relating to Employee Matters and Managing Growth
We may be unable to successfully integrate acquisitions, which may adversely impact our operations
DroppedRisks Relating to Employee Matters and Managing Growth
If we continue to progress the development of our product candidates, expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, we may encounter difficulties in managing our growth, which could disrupt our operations
DroppedRisks Related to Our Common Stock
The dual class structure of our common stock may limit our stockholders’ ability to influence corporate matters and may limit visibility with respect to certain transactions
DroppedRisks Related to Our Common Stock
Changes in tax legislation could adversely affect our business and financial condition
DroppedRisks Related to Our Common Stock
the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval, which preferred stock may include rights superior to the rights of the holders of common stock
DroppedRisks Related to Our Common Stock
Unfavorable global economic or political conditions could adversely affect our business, financial condition or results of operations
DroppedRisks Related to Our Common Stock
Our employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading
DroppedRisks Related to Our Common Stock
exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved and some of the disclosure requirements of the Dodd-Frank Act relating to compensation of executive officers
DroppedRisks Related to Our Common Stock
We will continue to incur costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance initiatives
DroppedRisks Related to Our Common Stock
Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
DroppedRisks Related to Our Common Stock
If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline

Reworded

99% rewrittenRisks Related to our Industry and Business
Our ability to use net operating loss carryforwards and other tax attributes may be limited, including as a result of the Merger
Updated U.S. federal and state NOL carryforward figures to $267.0 million and $81.5 million as of December 31, 2025.
Was: Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited
98% rewrittenRisks Related to Ownership of Our Common Stock
Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management
Added specific reference to Delaware General Corporation Law Section 203 prohibiting 15% stockholders from combining with us.
Was: Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management
96% rewrittenRisks Related to Commercialization of Our Product Candidates
neither experimental nor investigational
Expanded on the time-consuming process of obtaining government and third-party reimbursement, including required scientific and cost-effectiveness data.
93% rewrittenRisks Related to our Industry and Business
Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel
Added details on industry turnover, lack of formal employment agreements for certain executives, and severance benefits for voluntary resignation.
Was: Our future success depends on our ability to retain key executives and experienced scientists and to attract, retain and motivate qualified personnel
92% rewrittenRisks Related to Our Intellectual Property
Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect IMG-007 or any future product candidates
Clarified the transition date of March 16, 2013 for the America Invents Act first-to-file patent system.
Was: Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our current or future product candidates
81% rewrittenRisks Related to Government Regulation
injunctions or the imposition of civil or criminal penalties
Added a specific threat from the Supreme Court's June 2024 Loper Bright decision overturning the Chevron doctrine.
60% rewrittenRisks Related to Our Intellectual Property
We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop, manufacture and market IMG-007 or any future product candidates
Added reference to the European Union and an 18-month publication window for patent applications.
Was: We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might subject us to infringement claims or adversely affect our ability to develop and market our current or future product candidates
41% rewrittenRisks Related to Ownership of Our Common Stock
Our amended and restated bylaws designate specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with the Company
Specified that the Delaware Forum Provision excludes certain causes of action from the exclusive forum rule.
Was: Our bylaws designate specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us
37% rewrittenRisks Related to Government Regulation
Obtaining and maintaining regulatory approval of IMG-007 or any future product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of IMG-007 or any future product candidates in other jurisdictions
Was: Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions

All 80 risk factors

Headings as the filing states them, in filing order.

Risks Related to Our Limited Operating History, Financial Position and Need for Additional Capital

01We are a clinical-stage biopharmaceutical company with a limited operating history, which may make it difficult to evaluate our current business and predict our future performanceNew
02We expect to incur significant losses for the foreseeable future and may never achieve or maintain profitabilityNew
03our implementation of additional internal systems and infrastructure, including operational, financial and management information systemsNew

Risks Related to the Discovery and Development of our Product Candidates

04Our business is entirely dependent on the success of IMG-007 for the treatment of AD and for other potential indicationsNew
05Clinical trials are expensive, time-consuming, difficult to design and implement, and have an uncertain outcome. Further, we may encounter substantial delays in our clinical trialsNew
06failure to manufacture sufficient quantities of IMG-007 or any future product candidates for use in clinical trialsNew
07any future collaborators that conduct clinical trials may face any of the above issues, and may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for usNew
08have the product removed from the market after obtaining marketing approvalNew
09Enrollment and retention of patients in clinical trials is an expensive and time-consuming process subject to various external factors beyond our control that may cause delays or complicationsNew
10the risk that patients enrolled in clinical trials will not remain in the trial through the completion of evaluationNew
11We may not identify or discover other product candidates and may fail to capitalize on product candidates that may present a greater commercial opportunity or for which there is a greater likelihood of successNew
12a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payorsNew
13Our future preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at allNew
14The affected populations for IMG-007 or any future product candidates may be smaller than we or third parties currently project, which may affect the addressable markets for IMG-007 or any future product candidatesNew
15ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operationsNew
16International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospectsNew

Risks Related to Manufacturing and Our Reliance on Third Parties

17Our ability to generate revenue and achieve profitability from third party licensed product candidates also depends upon our ability to obtain and retain exclusivity on the licensed product candidates and related product candidates controlled by the licensorNew
18the priority of invention of patented technologyNew
19Pursuant to the terms of the license agreements with certain of our licensors, the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity or unenforceability of these patentsNew
20Our rights to develop and commercialize IMG-007 are subject, in part, to the terms and conditions of licenses granted to us by othersNew
21carrier disruptions or increased costs that are beyond our controlNew
22Some of our suppliers may experience disruption to their respective supply chain due to the effects of macroeconomic conditions, which could delay, prevent or impair our development or commercialization effortsNew
23collaborators may own or co-own intellectual property covering IMG-007 or any future product candidates that results from our collaborating with them, and in such cases, we may not have the exclusive right to commercialize such intellectual propertyNew

Risks Related to Commercialization of Our Product Candidates

24We face substantial competition from other pharmaceutical and biotechnology companies, and our operating results may suffer if we fail to compete effectivelyNew
25Coverage and reimbursement may be limited or unavailable in certain market segments for IMG-007 or any future product candidates, which could make it difficult for us to sell for IMG-007 or any future product candidates, if approved, profitablyNew
26neither experimental nor investigational96% rewritten
27Clinical trial subject injury and product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of IMG-007 or any future product candidates that we may developNew

Risks Related to Government Regulation

28The BLA and similar applications must also include significant information regarding the chemistry, manufacturing and controls for the product, including with respect to chain of identity and chain of custody of the productNew
29changes in the approval policies or regulations that render our preclinical and clinical data insufficient for approvalNew
30We have conducted and intend to conduct certain of our clinical trials globally. However, the FDA and other foreign equivalents may not accept data from such trials, in which case our development plans may be delayed, which could materially harm our businessNew
31We may seek special designations by the regulatory authorities to expedite regulatory approvals, but may not be successful in receiving these designations, and even if received, they may not benefit the development and regulatory approval processNew
32Obtaining and maintaining regulatory approval of IMG-007 or any future product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of IMG-007 or any future product candidates in other jurisdictions37% rewritten
33marketing approvals, our target market will be reduced and our ability to realize the full market potential of IMG-007 and any future product candidates will be harmedNew
34injunctions or the imposition of civil or criminal penalties81% rewritten
35We and any of our third-party manufacturers or suppliers may use potent chemical agents and hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costlyNew
36federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumersNew
37IMG-007 will be regulated as a biologic, and therefore they may be subject to competition sooner than anticipatedNew
38Even if we obtain regulatory approval of IMG-007 or any future product candidates, the products may not gain market acceptance among physicians, patients, hospitals and others in the medical communityNew
39the effectiveness of our sales and marketing effortsNew
40The advancement of healthcare reform may negatively impact our ability to profitably sell IMG-007 or any future product candidates, if approvedNew
41Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitabilityNew
42standards, external and internal privacy and security policies, contractual requirements and other obligations relating to data privacy and security, including in connection with clinical trials in the United States and abroadNew
43the violator. India’s new privacy legislation, the Digital Personal Data Protection Act (“DPDP”), may also apply to our operationsNew
44Our activities may subject us to various laws relating to foreign and U.S. investments and other transactions, and our failure to comply with these laws could subject us to substantial fines and other penalties, which could adversely affect our businessNew
45The CFIUS Regulations authorize CFIUS to review certain foreign investments in and acquisitions of U.S. businesses, and to prohibit, modify, or unwind transactions subject to CFIUS jurisdiction in the event the transaction is determined to raise national security concernsNew

Risks Related to Our Intellectual Property

46If we are unable to obtain and maintain patent protection for IMG-007 or any future product candidates or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our marketsNew
47We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop, manufacture and market IMG-007 or any future product candidates60% rewritten
48Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect IMG-007 or any future product candidates92% rewritten
49Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirementsNew
50We enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the worldNew
51If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of marketing exclusivity for IMG-007 or any future product candidates, our business may be harmedNew
52Our proprietary rights may not adequately protect IMG-007 or any future product candidates, and do not necessarily address all potential threats to our competitive advantageNew
53the patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on our businessNew
54If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affectedNew
55We may need to license additional intellectual property from third parties, and any such licenses may not be available or may not be available on commercially reasonable termsNew
56We may fail to obtain or enforce assignments of intellectual property rights from our employees and contractorsNew
57Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary informationNew
58We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third partiesNew

Risks Related to our Industry and Business

59We will need to expand our organization, and we may experience challenges in managing this growth as we build our capabilities, which could disrupt our operationsNew
60Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel93% rewritten
61Our business is subject to risks arising from pandemic and epidemic diseasesNew
62We or the third parties upon whom we depend may be adversely affected by a fire and earthquake or other man-made or natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disasterNew
63Our insurance policies may be inadequate, may not cover all of our potential liabilities and may potentially expose us to unrecoverable risksNew
64Our business could be affected by litigation, government investigations, and enforcement actionsNew
65Our employees and independent contractors, including consultants, vendors and any third parties we may engage in connection with development and commercialization may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could harm our businessNew
66Our ability to use net operating loss carryforwards and other tax attributes may be limited, including as a result of the Merger99% rewritten
67Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operationsNew

Risks Related to Ownership of Our Common Stock

68The market price of our common stock is expected to be volatileNew
69Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common stockNew
70We will incur significant legal, accounting and other expenses that Legacy Inmagene did not incur as a private company, including costs associated with public company reporting requirementsNew
71Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management98% rewritten
72Our amended and restated bylaws designate specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with the Company41% rewritten
73An active trading market for our common stock may not develop and our stockholders may not be able to resell their shares of common stock for a profit, if at allNew
74Substantial future sales of shares of our common stock could adversely affect the market price of such sharesNew
75If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could declineNew
76However, this material weakness could result in a misstatement of substantially all of our accounts or disclosures that would result in a material misstatement of our annual or interim financial statements that would not be prevented or detectedNew
77Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impairedNew
78The increasing use of social media platforms presents new risks and challengesNew
79Unstable market and economic conditions, including any adverse macroeconomic conditions or geopolitical events, may have serious adverse consequences on our business, financial condition and stock priceNew
80We could be subject to securities class action litigationNew

Other ImageneBio 10-Ks

FY2024 10-K risk factors
85 risks
ImageneBio faces risks centered on its pending merger with Insight Merger Sub, ongoing net losses, and clinical development in targeted oncology.
Filed Mar 06, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.